LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Home・Akciju saraksts・Abeona Therapeutics Inc

Abeona Therapeutics Inc

Slēgts

6.81 1.64

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.6

Max

6.84

Galvenie mērījumi
By Trading Economics
P/E Sektora vidējais	10.182 35.733
Darbinieki	136

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+198.51% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 12. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	11M 287M
Iepriekšējā atvēršanas cena	5.17
Iepriekšējā slēgšanas cena	6.81

Abeona Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. sept. 23:37 UTC

Karstas akcijas

Stocks to Watch: Oracle, Wearable Devices, GameStop

2025. g. 9. sept. 20:41 UTC

Peļņas

Oracle's Backlog Surges With Major Customer Deals in 1Q

2025. g. 9. sept. 20:30 UTC

Peļņas

GameStop 2Q Sales, Profit Rise

2025. g. 9. sept. 23:19 UTC

Tirgus saruna

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

2025. g. 9. sept. 21:35 UTC

Peļņas

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 21:32 UTC

Peļņas

Oracle's Backlog Swells With Big Customer Deals -- Update

2025. g. 9. sept. 21:02 UTC

Iegādes, apvienošanās, pārņemšana

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

2025. g. 9. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. sept. 20:33 UTC

Peļņas

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

2025. g. 9. sept. 20:26 UTC

Peļņas

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 20:23 UTC

Peļņas

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 20:12 UTC

Peļņas

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

2025. g. 9. sept. 20:10 UTC

Peļņas

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

2025. g. 9. sept. 20:10 UTC

Peļņas

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

2025. g. 9. sept. 20:09 UTC

Peļņas

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

2025. g. 9. sept. 20:09 UTC

Peļņas

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle 1Q Operating Income Was $4.3 B >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

2025. g. 9. sept. 20:07 UTC

Peļņas

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

2025. g. 9. sept. 20:06 UTC

Peļņas

Oracle 1Q Software Revenue $5.72B >ORCL

2025. g. 9. sept. 20:06 UTC

Peļņas

Synopsys 3Q Adj EPS $3.39 >SNPS

2025. g. 9. sept. 20:06 UTC

Peļņas

Oracle 1Q Cloud Revenue $7.19B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Rev $14.93B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q EPS $1.01 >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Synopsys 3Q EPS $1.50 >SNPS

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Services Revenue $1.35B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Adj EPS $1.47 >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Hardware Revenue $670M >ORCL

Salīdzinājums

Cenas izmaiņa

Abeona Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

198.51% augšup

Prognoze 12 mēnešiem

Vidējais 20 USD 198.51%

Augstākais 20 USD

Zemākais 20 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Abeona Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Abeona Therapeutics Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Par Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.